CARS2 and inflammatory bowel disease: Together our results indicate that dysregulated CARS2/CPERS-dependent supersulfide metabolism in CD4+ T cells can lead to intestinal inflammation, and further suggest the same metabolic pathway as a potential therapeutic target for IBD treatment.